|
|
|
26.02.26 - 19:30
|
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet (24/7 Wall St.)
|
|
|
A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week. The catalyst is Merck's February 23 announcement to split its Human Health business into two divisions: one ... Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
The post Merck Stock Jumps But Reddit Traders Are Getting Cold Feet appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 12:51
|
Merck Evolves Human Health Operating Structure to Support Portfolio Execution (Business Wire)
|
|
|
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success.
As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio.
In support of the new Human Health Business Unit structure, Jannie Oosthuizen has been appointed executive vice president and president, Oncology and MSD International. Oosthuizen most recently served as senior vice president and president, Merck Human Health U.S., where he oversaw P&L, strategy and commercialization for ...
|
|
|
|
|
|
|
|
|
|
|
13.02.26 - 16:45
|
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
|
|
|
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|